Clover Health Investments (NASDAQ:CLOV) Trading Down 5.7% – Time to Sell?

Posted by Brenda Bartman on Aug 17th, 2026

Clover Health Investments, Corp. (NASDAQ:CLOV – Get Free Report)’s share price traded down 5.7% on Monday . The stock traded as low as $4.29 and last traded at $4.3380. Approximately 1,485,480 shares changed hands during trading, a decline of 77% from the average daily volume of 6,414,258 shares. The stock had previously closed at $4.60.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CLOV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Clover Health Investments in a report on Wednesday, June 24th. Canaccord Genuity Group raised their price target on Clover Health Investments from $4.20 to $5.50 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. UBS Group lifted their price objective on shares of Clover Health Investments from $4.75 to $5.00 and gave the stock a “neutral” rating in a research note on Thursday, August 6th. Finally, Wall Street Zen cut Clover Health Investments from a “strong-buy” rating to a “buy” rating in a research note on Sunday. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Clover Health Investments currently has an average rating of “Hold” and an average target price of $4.33.

Read Our Latest Research Report on CLOV

Clover Health Investments Stock Performance

The firm’s fifty day moving average is $4.71 and its 200 day moving average is $3.24. The firm has a market cap of $2.25 billion, a P/E ratio of -84.88 and a beta of 2.48.

Clover Health Investments (NASDAQ:CLOV – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.01. Clover Health Investments had a negative return on equity of 4.20% and a negative net margin of 0.74%.The firm had revenue of $743.17 million for the quarter, compared to analyst estimates of $728.27 million.

Insider Buying and Selling

In related news, VP Joseph Frank Oldakowski sold 12,102 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $4.86, for a total transaction of $58,815.72. Following the completion of the sale, the vice president directly owned 299,067 shares in the company, valued at $1,453,465.62. This represents a 3.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Andrew Toy sold 87,798 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $4.65, for a total transaction of $408,260.70. Following the completion of the transaction, the chief executive officer directly owned 9,459,316 shares of the company’s stock, valued at $43,985,819.40. This trade represents a 0.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 638,483 shares of company stock worth $3,035,848 in the last ninety days. 23.51% of the stock is owned by insiders.

Institutional Investors Weigh In On Clover Health Investments

A number of institutional investors have recently added to or reduced their stakes in CLOV. Allworth Financial LP increased its stake in shares of Clover Health Investments by 218.9% in the third quarter. Allworth Financial LP now owns 9,509 shares of the company’s stock valued at $29,000 after buying an additional 6,527 shares during the period. Integrated Wealth Concepts LLC bought a new position in shares of Clover Health Investments during the 1st quarter worth about $37,000. Envestnet Asset Management Inc. acquired a new stake in Clover Health Investments in the second quarter valued at approximately $31,000. Abel Hall LLC acquired a new stake in Clover Health Investments in the 4th quarter valued at $27,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of Clover Health Investments in the 4th quarter worth about $29,000. 19.77% of the stock is owned by institutional investors.

Clover Health Investments Company Profile

(Get Free Report)

Clover Health Investments is a technology-driven healthcare company specializing in Medicare Advantage plans for senior populations. The company combines insurance coverage with a proprietary software platform to improve care coordination, outcomes tracking and cost management. By leveraging data analytics, Clover Health aims to deliver personalized care pathways and preventive interventions for its members.

At the core of Clover’s offering is its Clover Assistant platform, which aggregates clinical and claims data from multiple sources to create real-time insights for physicians and care teams.